Mogamulizumab, an anti-CCR4 monoclonal antibody, exhibits clinical activity in CCR4+ systemic and cutaneous T-cell lymphomas, and may be of some benefit in contrasting the cHL microenvironment [29]. Here, CCR4 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.